Overcoming the Limitations of Transition-Metal Catalysis in the Chemoenzymatic Dynamic Kinetic Resolution (DKR) of Atropisomeric Bisnaphthols by Kun Wang (134525)

“…Such a reliable ligand offers π* orbitals, allowing additional metal-to-ligand d−π* back-donation, which can significantly enhance coordination effects between the ligand and metal. …”

Overcoming the Limitations of Transition-Metal Catalysis in the Chemoenzymatic Dynamic Kinetic Resolution (DKR) of Atropisomeric Bisnaphthols by Kun Wang (134525)

“…Such a reliable ligand offers π* orbitals, allowing additional metal-to-ligand d−π* back-donation, which can significantly enhance coordination effects between the ligand and metal. …”

A Novel Type of PSMA-Targeting Ligands via β‑Branched Aromatic α‑Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity by Zong-Xiao Liu (22177765)

“…With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [⁶⁸Ga]Ga-<b>PSMA-617</b>, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks. …”

A Novel Type of PSMA-Targeting Ligands via β‑Branched Aromatic α‑Amino Acid Modification, Bearing Enhanced Tumor Targeting and Reduced Renal Toxicity by Zong-Xiao Liu (22177765)

“…With average renal uptake of less than 10%ID/g, as opposed to 25%ID/g for [⁶⁸Ga]Ga-<b>PSMA-617</b>, this substantial decrease in renal accumulation translates to a significantly improved safety profile by minimizing nephrotoxic risks. …”

Changes in the mRNA integrity of ATP synthase subunits in maize seed embryos stored under different conditions. by Junming Zhang (5446787)

Colon length changes according to IBD-exacerbated factors in Il2rg-deficient mice. by Sun-Min Seo (13154880)

Characteristics of studied included. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Flowchart of the search process. by Razieh Bidhendi-Yarandi (7139387)

Subjects:

Excluded skewed studies. by Solima Sabeel (9545738)

Subjects:

Stratified meta-analysis for treatment duration effects of statins versus placebo subdivided into 3-4 months and longer than 4 months of treatment for by Solima Sabeel (9545738)

Subjects:

Reason for exclusion of all 6514 screened articles. by Solima Sabeel (9545738)

Subjects:

Methodological items for non-randomized studies (MINORS). by Solima Sabeel (9545738)

Subjects:

Jadad Score of randomized controlled trials. by Solima Sabeel (9545738)

Subjects:

Summary of randomized controlled trials. by Solima Sabeel (9545738)

Subjects:

LDL-C meta-analysis showing in (A) the overall effects of different statin types versus placebo and (B) stratified by statin treatment duration for 3-4 months and longer than 4 mon... by Solima Sabeel (9545738)

Subjects:

Summary table showing analysis of randomized controlled trials stratified based on age groups. by Solima Sabeel (9545738)

Subjects:

Meta-analysis showing the overall effect of different statin types versus placebo for by Solima Sabeel (9545738)

Subjects:

Version 2 of the Cochrane risk-of-bias tool for randomized controlled trials. by Solima Sabeel (9545738)

Subjects:

Analysis of randomized controlled trials stratified based on treatment duration. by Solima Sabeel (9545738)

Subjects:

Funnel plots of studies included in the meta-analysis assessing by Solima Sabeel (9545738)

Subjects: